Tetra Natural Health’s Distribution Partner Expands Distribution Network for the Hemp Energy Drink
ORLEANS, Ontario, Jan. 28, 2019 (GLOBE NEWSWIRE) — Tetra Bio-Pharma Inc (“Tetra” or the “Company”) (TSX VENTURE: TBP) (OTCQB: TBPMF), a leader in cannabinoid-based drug discovery and development has announced that it filed a patent application for its PPP001 drug product. Tetra’s research has led to a significant discovery that has enabled the company to apply for patent protection.
Tetra’s research demonstrated that the class II medical device or pipe used to combust the PPP001 drug pellet generates a unique composition of medicinal ingredients. This composition is significantly different from that created when heating the drug pellet in a vaporizer. The data demonstrated that the drug produced by combustion is different from that of the vapor and may partly explain the recognized efficacy of smoked cannabis. The composition of the remaining chemicals was expected to be different between smoke and vapor. This led the Corporation to implement two separate drug development paths and allow Tetra to commence developing second generation drugs for inhalation.
The patent covers methods of fabrication and composition of matter. “This patent application, if granted, would provide Tetra with full protection of its PPP001 prescription drug product placing PPP001 in the same category as any other innovative prescription drug,” said Dr. Guy Chamberland, CEO and CSO of Tetra Bio-Pharma. “This will give Tetra a much longer period of exclusivity. We recognize the inherent value of our intellectual property and the necessity to seek appropriate patents, to the extent possible, to protect our shareholders’ investments in the Company.”
Dr. Chamberland further stated, “In addition, we are pleased to announce that Tetra Natural Health’s exclusive distribution partner, Kombucha Baby Brewing Company, has advised us that our Hemp Energy Drink will be made available in a number of additional outlets in Ontario and Quebec in the not too distant future. We are very encouraged by the reaction of the market since its introduction in Q4 2018.”
About Tetra Bio-Pharma:
Tetra Bio-Pharma (TSX-V: TBP) (OTCQB: TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a Health Canada approved, and FDA reviewed, clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries engaged in the development of an advanced and growing pipeline of Bio Pharmaceuticals, Natural Health and Veterinary Products containing cannabis and other medicinal plant-based elements. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.
For more information visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding: the anticipated benefits of the Proposed Transaction for Tetra; completion and expected timing of the Proposed Transaction; whether the terms of the Proposed Transaction will be as described in this press release; whether the Proposed Transaction will be successful; the receipt of the approval of the TSXV in respect of the Proposed Transaction) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research and development strategies, the success of PPP001 and the Hemp Energy Drink, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process including the applications for Orphan Drug Designation, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. No definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
|For further information, please contact Tetra Bio-Pharma Inc.|
|Guy Chamberland, Ph.D.,|
|Chief Executive Officer and Chief Scientific Officer|
|Carol Levine||Stephanie Engel|
|514-288-8500 ext. 226||416-425-9143 ext. 209|
Source: Tetra Bio-Pharma Inc